DEF: Kairos Pharma 2026 Annual Meeting Proxy Statement

Kairos Pharma has issued its 2026 proxy statement detailing proposals for director elections, auditor ratification, a reverse stock split, and equity plan amendments.

Summary

• The 2026 Annual Meeting of Stockholders is scheduled for June 29, 2026, via virtual-only webcast.
• Proposal 1: Election of four directors: John S. Yu, Hyun W. Bae, Hansoo Michael Keyoung, and Rahul Singhvi.
• Proposal 2: Ratification of Weinberg & Company, P.A. as the independent registered public accounting firm for 2026.
• Proposal 3: Approval of a reverse stock split at a ratio between 1:3 and 1:250, at the Board's discretion.
• Proposal 4: Advisory vote on executive compensation.
• Proposal 5: Amendment to the 2023 Equity Incentive Plan to increase the share pool by 5,000,000 shares and adopt a 5% annual evergreen provision for ten years.
• The record date for voting is May 15, 2026, with 21,411,198 shares of common stock outstanding.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a defensive filing, as the primary proposals (reverse stock split and significant equity dilution) suggest the company is struggling with share price maintenance and liquidity.

Positives

• The company is seeking to improve marketability and liquidity of its common stock through a potential reverse stock split.
• The proposed evergreen provision for the equity plan aims to reduce future administrative costs and time associated with seeking shareholder approval for share pool increases.
• The board maintains a majority of independent directors (3 out of 4).
• The company has adopted a clawback policy for executive compensation.

Negatives

• The proposed reverse stock split ratio is aggressive, reaching up to 1:250, which may signal significant past share price erosion.
• The equity plan amendment significantly increases potential dilution through both a 5 million share addition and a 5% annual evergreen provision.
• The company has a history of late Section 16(a) filings by directors and executive officers during 2025.
• The company has relied on loans from officers to maintain operations, indicating potential liquidity constraints.

Risks

• The reverse stock split may not achieve the intended goal of a sustained increase in share price.
• The reverse stock split could lead to reduced trading liquidity and a smaller number of market makers.
• The company may face a decrease in overall market capitalization if the market views the reverse split negatively.
• The company is an emerging growth company and a smaller reporting company, which limits the amount of financial and compensation disclosure required.
• The company has a history of operating losses and may require additional capital in the future.

Future Outlook

The company intends to continue advancing its pipeline to address cancer therapeutic resistance and suppressed immune responses, while utilizing the proposed reverse stock split and equity plan amendments to support its capital structure and talent retention strategies.

Management Comments

• The Board believes that the Reverse Stock Split may result in an increase in the market price of our Common Stock, which could lead to increased interest in our Common Stock.
• We believe that the additional 5,000,000 shares and the evergreen clause will provide sufficient authorized shares available under the 2023 Equity Incentive Plan for the grant of awards for the next several years.

Industry Context

StockSavvy.ai notes that Kairos Pharma's reliance on reverse stock splits and aggressive equity plan expansions is common among micro-cap biotechnology firms struggling to maintain listing compliance on exchanges like the NYSE American while attempting to retain specialized scientific talent.

Comparison to Industry Standards

• The use of a 1:3 to 1:250 reverse stock split range is highly aggressive compared to standard market practice, which typically targets lower ratios.
• The 5% annual evergreen provision is on the higher end of standard equity compensation practices for small-cap biotech companies.
• The virtual-only meeting format is increasingly common for smaller reporting companies to reduce administrative costs.

Corporate Governance

Related Party Transactions

• The company has historically borrowed funds from officers, including loans at 7.5% interest per annum, which were subsequently converted into common stock.

Stakeholder Impact

• Shareholders face potential dilution from the proposed equity plan expansion.
• Shareholders may experience volatility due to the proposed reverse stock split.
• Employees and directors stand to benefit from the increased availability of equity-based compensation.

Next Steps

• Hold the 2026 Annual Meeting of Stockholders on June 29, 2026.
• File a Form 8-K within four business days of the meeting to report voting results.
• Potentially implement a reverse stock split at the Board's discretion.

Key Dates

Recommendation

The company is in a precarious position, evidenced by the need for a massive reverse stock split and ongoing reliance on officer loans. While the technology pipeline may have potential, the current corporate actions suggest significant financial distress and dilution risk for retail investors.

Keywords

Kairos Pharma, KAPA, Reverse Stock Split, Proxy Statement, Biotech, Equity Incentive Plan, Corporate Governance